ADMA Stock Risk & Deep Value Analysis

ADMA Biologics Inc

DVR Score

9.3

out of 10

Hidden Gem

The Bottom Line on ADMA

We analyzed ADMA Biologics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran ADMA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Mar 15, 2026•Run Fresh Analysis →

📈ADMA Performance Overview3yr weekly

📊

Unlock ADMA Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

ADMA Stock Risk Analysis

Overall Risk

Moderate

Financial Risk

Medium

Market Risk

Low

ADMA Deep Value Analysis

ADMA Biologics continues to demonstrate strong execution and momentum in the undersupplied IVIG market. Its vertical integration strategy is proving highly effective, enhancing supply control and driving significant margin expansion. The company has sustained its transition to profitability with accelerating revenue growth and positive cash flow, validating its strategic pivot. Expansion of plasma collection centers and the differentiated ASCENIV product strengthen its competitive moat and market share potential. Favorable debt management and growing institutional interest further de-risk the investment, positioning ADMA for continued robust growth and significant market leadership within the 3-5 year horizon, making it a compelling high-reward opportunity.

ADMA Red Flags & Warning Signs

Premium

⚠
Lower-than-expected Q1 2026 earnings or cautious FY2026 guidance (Q2 2026)
⚠
Increased competitive pressure or pricing erosion from larger players
⚠
Slower-than-anticipated plasma center ramp-ups or collection volume growth
⚠
Supply chain disruptions impacting plasma fractionation

Unlock ADMA Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

ADMA Competitive Moat Analysis

Premium

Moat Rating

Narrow

Moat Trend

Expanding

Moat Sources

4 Identified

Cost Advantages (through vertical integration and operational efficiencies)Intangible Assets/IP (proprietary product, ASCENIV, and manufacturing processes)Efficient Scale (growing network of plasma collection centers and optimized fractionation capacity)Regulatory Hurdles (high barriers to entry for new players in plasma derivatives)

The moat is strengthening due to increasing vertical integration, which reduces external supply reliance and costs, coupled with a differentiated product and the high regulatory and capital intensity of the plasma industry. This makes it difficult for new entrants to compete effectively.

ADMA Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

ADMA Catalysts & Growth Drivers

Near-Term (0-6 months)

•Q1 2026 Earnings Report (estimated late April 2026)
•Announcement of 2-3 new plasma center openings in Q2 2026
•Updated FY2026 revenue and margin guidance

Medium-Term (6-18 months)

•Continued significant increases in plasma collection volumes and capacity utilization (H2 2026 - H1 2027)
•Potential strategic partnership for international market expansion (late 2026)
•Completion of debt refinancing to further reduce interest expenses and enhance flexibility (early 2027)

Long-Term (18+ months)

•Achievement of significant market share in the U.S. IVIG market (2028-2029)
•Potential approval for additional indications for ASCENIV or new product pipeline advancement (2029+)
•Becoming a key player in the global plasma-derived therapeutics market (2030+)

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

ADMA Bull Case: What Could Go Right

✓
Acceleration in gross margin expansion and sustained positive operating cash flow
✓
Consistent reporting of new plasma center openings and increasing plasma collection volumes
✓
Successful execution of debt reduction or refinancing efforts

Bull Case Analysis

See what could go right with Premium

🔔

Never miss a move on ADMA

Create a free account to set price alerts and get notified on Telegram when ADMA hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for ADMA Biologics Inc (ADMA)?

As of March 15, 2026, ADMA Biologics Inc has a DVR Score of 9.3 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the risk level for ADMA stock?

Our analysis rates ADMA Biologics Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the ADMA DVR analysis updated?

Our AI-powered analysis of ADMA Biologics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 15, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.